Cover Image
市場調查報告書

PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 現在·未來的主要企業

PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players

出版商 GlobalData 商品編碼 325952
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:黃斑部水腫 (ME) 和黃斑部病變 (MD) - 現在·未來的主要企業 PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players
出版日期: 2014年10月31日 內容資訊: 英文 85 Pages
簡介

本報告提供全球黃斑部水腫 (ME) 和黃斑部病變 (MD) 的治療藥市場相關調查分析,提供您以構成市場的主要企業 (新加入企業) 為焦點,提供您競爭情形相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素與阻礙

第4章 現在·未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Roche/Genentech
    • Novartis
    • Regeneron
    • Bayer
    • Valeant
    • Allergan
    • Alimera Sciences
    • Ampio Pharmaceuticals
    • Ophthotech
    • Acucela
    • Ohr Pharmaceuticals

第5章 附錄

圖表

目錄
Product Code: GDHC1040FPR

GlobalData has released its pharma report, "PharmaPoint: Macular Edema and Macular Degeneration - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Macular Edema and Macular Degeneration. The report identifies and analyses the key companies shaping and driving the global Macular Edema and Macular Degeneration market. The report provides insight into the competitive Macular Edema and Macular Degeneration landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Macular Edema and Macular Degeneration
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Macular Edema and Macular Degeneration sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Macular Edema and Macular Degeneration market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Macular Edema and Macular Degeneration market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Roche/Genentech
    • 4.3.2. Novartis
    • 4.3.3. Regeneron
    • 4.3.4. Bayer
    • 4.3.5. Valeant
    • 4.3.6. Allergan
    • 4.3.7. Alimera Sciences
    • 4.3.8. Ampio Pharmaceuticals
    • 4.3.9. Ophthotech
    • 4.3.10. Acucela
    • 4.3.11. Ohr Pharmaceuticals

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed ME and AMD Patients
    • 5.4.2. Percentage of Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
  • 5.5. Primary Research - KOLs Interviewed for this Report
  • 5.6. Primary Research - High-Prescribers Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Therapy Area Director
    • 5.7.3. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for ME, 2013-2023
  • Table 2: Global Sales Forecast ($m) for AMD, 2013-2023
  • Table 3: ME and AMD Markets - Drivers and Barriers, 2013-2023
  • Table 4: Key Companies in the ME and AMD Markets in the 7MM, 2014
  • Table 5: Roche/Genentech's ME and AMD Portfolio Assessment, 2014
  • Table 6: Novartis' ME and AMD Portfolio Assessment, 2014
  • Table 7: Regeneron's ME and AMD Portfolio Assessment, 2014
  • Table 8: Bayer's ME and AMD Portfolio Assessment, 2014
  • Table 9: Valeant's AMD Portfolio Assessment, 2014
  • Table 10: Allergan's ME and AMD Portfolio Assessment, 2014
  • Table 11: Alimera Sciences' ME Portfolio Assessment, 2014
  • Table 12: Ampio's ME Portfolio Assessment, 2014
  • Table 13: Ophthotech's AMD Portfolio Assessment, 2014
  • Table 14: Acucela's AMD Portfolio Assessment, 2014
  • Table 15: Ohr Pharmaceutical's AMD Portfolio Assessment, 2014
  • Table 16: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Global Sales for ME by Region, 2013-2023
  • Figure 2: Individual Drug Sales for ME 2013-2023
  • Figure 3: Global Sales for AMD by Region, 2013-2023
  • Figure 4: Individual Drug Sales for AMD 2013-2023
  • Figure 5: Global Sales of Branded Products for ME and AMD by Company, 2013-2023
  • Figure 6: Company Portfolio Gap Analysis in ME and AMD, 2013-2023
  • Figure 7: Roche/Genentech's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 8: Novartis' SWOT Analysis in ME and AMD, 2013-2023
  • Figure 9: Regeneron's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 10: Bayer's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 11: Valeant's SWOT Analysis in AMD, 2013-2023
  • Figure 12: Allergan's SWOT Analysis in ME and AMD, 2013-2023
  • Figure 13: Alimera Sciences' SWOT Analysis in ME, 2013-2023
  • Figure 14: Ampio's SWOT Analysis in ME, 2013-2023
  • Figure 15: Ophthotech's SWOT Analysis in AMD, 2013-2023
  • Figure 16: Acucela's SWOT Analysis in AMD, 2013-2023
  • Figure 17: Ohr Pharmaceutical's SWOT Analysis in AMD, 2013-2023
Back to Top